Role of Nectin‑4 protein in cancer (Review)
- Authors:
- Yongheng Liu
- Xiuxin Han
- Lili Li
- Yanting Zhang
- Xiaoyu Huang
- Guanghao Li
- Chuncai Xu
- Mengfan Yin
- Peng Zhou
- Fanqi Shi
- Xiaozhi Liu
- Yan Zhang
- Guowen Wang
-
Affiliations: Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Central Laboratory, The Fifth Central Hospital of Tianjin, Tianjin 300450, P.R. China - Published online on: October 19, 2021 https://doi.org/10.3892/ijo.2021.5273
- Article Number: 93
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, et al: SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 511:246–250. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chothia C and Jones EY: The molecular structure of cell adhesion molecules. Annu Rev Biochem. 66:823–862. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Reymond N, Fabre S, Lecocq E, Adelaïde J, Dubreuil P and Lopez M: Nectin4/PRR4, a new Afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem. 276:43205–43215. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G and Lopez M: Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C′-C′-D beta-strands of the nectin1 V domain. J Biol Chem. 277:27006–27013. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Yasumi M, Shimizu K, Honda T, Takeuchi M and Takai Y: Role of each immunoglobulin-like loop of nectin for its cell-cell adhesion activity. Biochem Biophys Res Commun. 302:61–66. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Takai Y, Miyoshi J, Ikeda W and Ogita H: Nectins and nectin-like molecules: Roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 9:603–615. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sakisaka T, Ikeda W, Ogita H, Fujita N and Takai Y: The roles of nectins in cell adhesions: Cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol. 19:593–602. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nakanishi H and Takai Y: Roles of nectins in cell adhesion, migration and polarization. Biol Chem. 385:885–892. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M and Elledge SJ: A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2:e003582013. View Article : Google Scholar : PubMed/NCBI | |
|
Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al: Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM and Skubitz AP: Nectin 4 overexpression in ovarian cancer tissues and serum: Potential role as a serum biomarker. Am J Clin Pathol. 134:835–845. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lin X, Hu H, Pan Y and Gao S: The prognostic role of expression of Nectin-4 in esophageal cancer. Med Sci Monit. 25:10089–10094. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R, Adélaïde J, Geneix J, et al: Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer. 7:732007. View Article : Google Scholar : PubMed/NCBI | |
|
Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N and Nakajima Y: Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 34:302015. View Article : Google Scholar : PubMed/NCBI | |
|
Sakisaka T and Takai Y: Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol. 16:513–521. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada A, Fujita N, Sato T, Okamoto R, Ooshio T, Hirota T, Morimoto K, Irie K and Takai Y: Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells. Oncogene. 25:5085–5102. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez M, Aoubala M, Jordier F, Isnardon D, Gomez S and Dubreuil P: The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood. 92:4602–4611. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Reymond N, Borg JP, Lecocq E, Adelaide J, Campadelli-Fiume G, Dubreuil P and Lopez M: Human nectin3/PRR3: A novel member of the PVR/PRR/nectin family that interacts with Afadin. Gene. 255:347–355. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Takai Y and Nakanishi H: Nectin and Afadin: Novel organizers of intercellular junctions. J Cell Sci. 116:17–27. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Takai Y, Irie K, Shimizu K, Sakisaka T and Ikeda W: Nectins and nectin-like molecules: Roles in cell adhesion, migration, and polarization. Cancer Sci. 94:655–667. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, Tsao MS and Richardson CD: Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 7:e10022402011. View Article : Google Scholar : PubMed/NCBI | |
|
Bojesen KB, Clausen O, Rohde K, Christensen C, Zhang L, Li S, Køhler L, Nielbo S, Nielsen J, Gjørlund MD, et al: Nectin-1 binds and signals through the fibroblast growth factor receptor. J Biol Chem. 287:37420–37433. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kanzaki N, Ogita H, Komura H, Ozaki M, Sakamoto Y, Majima T, Ijuin T, Takenawa T and Takai Y: Involvement of the nectin-Afadin complex in PDGF-induced cell survival. J Cell Sci. 121:2008–2017. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ogita H and Takai Y: Cross-talk among integrin, cadherin, and growth factor receptor: Roles of nectin and nectin-like molecule. Int Rev Cytol. 265:1–54. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez-Rico C, Pincet F, Perez E, Thiery JP, Shimizu K, Takai Y and Dufour S: Separation force measurements reveal different types of modulation of E-cadherin-based adhesion by nectin-1 and −3. J Biol Chem. 280:4753–4760. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Xie X, Zhang X, Jia W, Jian J, Song C and Jin B: The expression, regulation and adhesion function of a novel CD molecule, CD226, on human endothelial cells. Life Sci. 73:2373–2382. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A, Onodera M, Sumida T, Nakauchi H, Miyoshi H and Shibuya A: CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med. 198:1829–1839. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA. 106:17858–17863. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 10:48–57. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S and Mandelboim O: Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 43:2138–2150. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Xia P, Du Y, Liu S, Huang G, Chen J, Zhang H, Hou N, Cheng X, Zhou L, et al: T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem. 289:17647–17657. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Zhang H, Li M, Hu D, Li C, Ge B, Jin B and Fan Z: Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 20:456–464. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al: The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 26:923–937. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi K, Nakanishi H, Miyahara M, Mandai K, Satoh K, Satoh A, Nishioka H, Aoki J, Nomoto A, Mizoguchi A and Takai Y: Nectin/PRR: An immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol. 145:539–549. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Samanta D and Almo SC: Nectin family of cell-adhesion molecules: Structural and molecular aspects of function and specificity. Cell Mol Life Sci. 72:645–658. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shankar J and Nabi IR: Correction: Actin cytoskeleton regulation of epithelial mesenchymal transition in metastatic cancer cells. PLoS One. 10:e01327592015. View Article : Google Scholar : PubMed/NCBI | |
|
Irie K, Shimizu K, Sakisaka T, Ikeda W and Takai Y: Roles and modes of action of nectins in cell-cell adhesion. Semin Cell Dev Biol. 15:643–656. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu K and Takai Y: Roles of the intercellular adhesion molecule nectin in intracellular signaling. J Biochem. 134:631–636. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda W, Nakanishi H, Miyoshi J, Mandai K, Ishizaki H, Tanaka M, Togawa A, Takahashi K, Nishioka H, Yoshida H, et al: Afadin: A key molecule essential for structural organization of cell-cell junctions of polarized epithelia during embryogenesis. J Cell Biol. 146:1117–1132. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, Adélaïde J, Geneix J, Xerri L, Dubreuil P, et al: Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene. 26:298–307. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fukuyama T, Ogita H, Kawakatsu T, Fukuhara T, Yamada T, Sato T, Shimizu K, Nakamura T, Matsuda M and Takai Y: Involvement of the c-Src-Crk-C3G-Rap1 signaling in the nectin-induced activation of Cdc42 and formation of adherens junctions. J Biol Chem. 280:815–825. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kawakatsu T, Ogita H, Fukuhara T, Fukuyama T, Minami Y, Shimizu K and Takai Y: Vav2 as a Rac-GDP/GTP exchange factor responsible for the nectin-induced, c-Src- and Cdc42-mediated activation of Rac. J Biol Chem. 280:4940–4947. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Takai Y, Ikeda W, Ogita H and Rikitake Y: The immunoglobulin-like cell adhesion molecule nectin and its associated protein Afadin. Annu Rev Cell Dev Biol. 24:309–342. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Okabe N, Shimizu K, Ozaki-Kuroda K, Nakanishi H, Morimoto K, Takeuchi M, Katsumaru H, Murakami F and Takai Y: Contacts between the commissural axons and the floor plate cells are mediated by nectins. Dev Biol. 273:244–256. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmad F, Nasir A, Thiele H, Umair M, Borck G and Ahmad W: A novel homozygous missense variant in NECTIN4 (PVRL4) causing ectodermal dysplasia cutaneous syndactyly syndrome. Ann Hum Genet. 82:232–238. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Brancati F, Fortugno P, Bottillo I, Lopez M, Josselin E, Boudghene-Stambouli O, Agolini E, Bernardini L, Bellacchio E, Iannicelli M, et al: Mutations in PVRL4, encoding cell adhesion molecule Nectin-4, cause ectodermal dysplasia-syndactyly syndrome. Am J Hum Genet. 87:265–473. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, et al: Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76:3003–3013. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z, Lu W, Wang XA, Zhang F, Cao Y, et al: A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 375:179–189. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang J, Shen Q, Yin W, Huang H, Liu Y and Ni Q: High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 15:8789–8795. 2018.PubMed/NCBI | |
|
Zhang Y, Chen P, Yin W, Ji Y, Shen Q and Ni Q: Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Hum Pathol. 72:107–116. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Das D, Satapathy SR, Siddharth S, Nayak A and Kundu CN: Nectin-4 increased the 5-FU resistance in colon cancer cells by inducing the PI3K-AKT cascade. Cancer Chemother Pharmacol. 76:471–479. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Liu K, Peng P, Li S, Ye Z, Su Y, Liu S, Qin M and Huang J: Upregulation of Nectin-4 is associated with ITGB1 and vasculogenic mimicry and may serve as a predictor of poor prognosis in colorectal cancer. Oncol Lett. 18:1163–1170. 2019.PubMed/NCBI | |
|
Siddharth S, Nayak A, Das S, Nayak D, Panda J, Wyatt MD and Kundu CN: The soluble Nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-β4. Int J Biochem Cell Biol. 102:151–160. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Siddharth S, Goutam K, Das S, Nayak A, Nayak D, Sethy C, Wyatt MD and Kundu CN: Nectin-4 is a breast cancer stem cell marker that induces WNT/β-catenin signaling via Pi3k/Akt axis. Int J Biochem Cell Biol. 89:85–94. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Deng H, Shi H, Chen L, Zhou Y and Jiang J: Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int. 19:1062019. View Article : Google Scholar : PubMed/NCBI | |
|
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang E, Marincola FM, Mai C, Chen Y, Wei H, et al: Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. Cell Death Dis. 4:e6342013. View Article : Google Scholar : PubMed/NCBI | |
|
Bousquet E, Calvayrac O, Mazières J, Lajoie-Mazenc I, Boubekeur N, Favre G and Pradines A: RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene. 35:1760–1769. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Karlsson R, Pedersen ED, Wang Z and Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 1796:91–98. 2009.PubMed/NCBI | |
|
Schmidt A and Hall A: Guanine nucleotide exchange factors for Rho GTPases: Turning on the switch. Genes Dev. 16:1587–1609. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, et al: R-ketorolac targets Cdc42 and Rac1 GTPases and alters ovarian tumor cell behaviors critical for invasion and metastasis. Cancer Res. 75 (Suppl 15):S40442015. | |
|
Vial E, Sahai E and Marshall CJ: ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T and Gutkind JS: The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 81:1137–1146. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Eswaran J, Li DQ, Shah A and Kumar R: Molecular pathways: Targeting p21-activated kinase 1 signaling in cancer-opportunities, challenges, and limitations. Clin Cancer Res. 18:3743–3749. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Henderson V, Smith B, Burton LJ, Randle D, Morris M and Odero-Marah VA: Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Cell Adh Migr. 9:255–264. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ray RM, Vaidya RJ and Johnson LR: MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil Cytoskeleton. 64:143–156. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Slabáková E, Pernicová Z, Slavíčková E, Staršíchová A, Kozubík A and Souček K: TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug. Prostate. 71:1332–1343. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hao RT, Zheng C, Wu CY, Xia EJ, Zhou XF, Quan RD and Zhang XH: NECTIN4 promotes papillary thyroid cancer cell proliferation, migration, and invasion and triggers EMT by activating AKT. Cancer Manag Res. 11:2565–2578. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M and Athanassiadou P: The significance of survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol. 49:26–33. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rajc J, Gugić D, Fröhlich I, Marjanović K and Dumenčić B: Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer. Pathol Res Pract. 213:1102–1108. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, et al: Nectin-4: A new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 28:769–776. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zeindler J, Soysal SD, Piscuoglio S, Ng CKY, Mechera R, Isaak A, Weber WP, Muenst S and Kurzeder C: Nectin-4 expression is an independent prognostic biomarker and associated with better survival in triple-negative breast cancer. Front Med (Lausanne). 6:2002019. View Article : Google Scholar : PubMed/NCBI | |
|
Lattanzio R, Ghasemi R, Brancati F, Sorda RL, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali PG and Piantelli M: Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. Oncogenesis. 3:e1182014. View Article : Google Scholar : PubMed/NCBI | |
|
Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P and Lopez M: Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem. 280:19543–19550. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL and Skubitz AP: Differential gene expression in ovarian carcinoma: Identification of potential biomarkers. Am J Pathol. 165:397–414. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nabih ES, Abdel Motaleb FI and Salama FA: The diagnostic efficacy of nectin 4 expression in ovarian cancer patients. Biomarkers. 19:498–504. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Boylan KL, Buchanan PC, Manion RD, Shukla DM, Braumberger K, Bruggemeyer C and Skubitz AP: The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate. Oncotarget. 8:9717–9738. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, et al: Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Cancer Cell. 26:77–91. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Desoize B and Jardillier J: Multicellular resistance: A paradigm for clinical resistance? Crit Rev Oncol Hematol. 36:193–207. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Boylan KLM, Manion RD, Shah H, Skubitz KM and Skubitz APN: Inhibition of ovarian cancer cell spheroid formation by synthetic peptides derived from Nectin-4. Int J Mol Sci. 21:46372020. View Article : Google Scholar : PubMed/NCBI | |
|
Erturk K, Karaman S, Dagoglu N, Serilmez M, Duranyildiz D and Tas F: Serum Nectin-2 and Nectin-4 are diagnostic in lung cancer: Which is superior? Wien Klin Wochenschr. 131:419–426. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M and Gao J: Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 31:207–215. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, et al: Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 21:53902020. View Article : Google Scholar : PubMed/NCBI | |
|
Izumi H, Hirabayashi K, Nakamura N and Nakagohri T: Nectin expression in pancreatic adenocarcinoma: Nectin-3 is associated with a poor prognosis. Surg Today. 45:487–494. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Sheng Z, Lv Y, Liu W, Yao Q, Pan T, Xu Z, Zhang C and Xu G: Expression and clinical significance of Nectin-4 in hepatocellular carcinoma. Onco Targets Ther. 9:183–190. 2016.PubMed/NCBI | |
|
Thomas A, Teicher BA and Hassan R: Antibody-drug conjugates for cancer therapy. Lancet Oncol. 17:e254–e262. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sarfaty M and Rosenberg JE: Antibody-drug conjugates in urothelial carcinomas. Curr Oncol Rep. 22:132020. View Article : Google Scholar : PubMed/NCBI | |
|
Leyton JV: Improving receptor-mediated intracellular access and accumulation of antibody therapeutics-the tale of HER2. Antibodies (Basel). 9:322020. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, et al: Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 37:2592–2600. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bednova O and Leyton JV: Targeted molecular therapeutics for bladder cancer-a new option beyond the mixed fortunes of immune checkpoint inhibitors? Int J Mol Sci. 21:72682020. View Article : Google Scholar : PubMed/NCBI | |
|
No authors listed. Targeting Nectin-4 in bladder cancer. Cancer Discov. 7:OF32017. View Article : Google Scholar | |
|
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, et al: EV-101: A phase I study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 38:1041–1049. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, et al: Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 22:872–882. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hoimes CJ, Rosenberg JE, Petrylak DP, Carret AS, Sasse C, Chaney MF and Flaig TW: Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer. J Clin Oncol. 38 (Suppl 6):TPS5952020. View Article : Google Scholar | |
|
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, et al: Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 384:1125–1135. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Delpeut S, Sisson G, Black KM and Richardson CD: Measles virus enters breast and colon cancer cell lines through a PVRL4-mediated macropinocytosis pathway. J Virol. 91:e02191–16. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Griffin DE and Oldstone MB: Measles: History and basic biology. Introduction. Curr Top Microbiol Immunol. 329:12009.PubMed/NCBI | |
|
Bluming AZ and Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet. 2:105–106. 1971. View Article : Google Scholar : PubMed/NCBI | |
|
Taqi AM, Abdurrahman MB, Yakubu AM and Fleming AF: Regression of Hodgkin's disease after measles. Lancet. 1:11121981. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Peng KW and Russell SJ: Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther. 23:295–301. 2012. View Article : Google Scholar : PubMed/NCBI |
